Abstract
Immune checkpoint inhibitors combined with chemotherapy have become standard-of-care first-line treatment for ES-SCLC in recent years. In the phase III CASPIAN study, the PD-L1 inhibitor durvalumab, in combination with platinum-etoposide (EP), demonstrated a statistically significant improvement in overall survival (OS) vs EP alone in first-line treatment of ES-SCLC (HR 0.73 [95% CI 0.59-0.91; p=0.0047]); OS benefit was sustained after >3 years median follow-up (HR 0.71 [95% CI 0.60‒0.86; nominal p=0.0003]).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
